Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1

Fibrinolysis and Proteolysis

Volumn 13, Issue 6, 1999, Pages 220-225

  Noel A ^a   Bajou, K ^a   Masson, V ^a   Devy, L ^a   Frankenne, F ^a   Rakic, J M ^b   Lambert, V ^a   Carmeliet, P ^c   Foidart, J M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANGIOGENESIS; CANCER INVASION; HUMAN; METASTASIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TUMOR BLOOD FLOW; VASCULARIZATION;

EID: 0033510477     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1054/fipr.2000.0043     Document Type: Review

References (45)

1. Noël A, Foidart JM. The role of extracellular matrix and fibroblasts in breast carcinoma growth in vivo. J Mamm Gland Biol Neopl 1998; 3: 215-225.
2. Noël A, Gilles C, Bajou et al. Emerging roles for proteinases in cancer. Invasion Metast 1997; 17: 221-239.
3. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (Review), Int J Oncol 1998; 13: 893-906.
4. Rifkin DB, Mazzieri R, Munger JS, Noguera I, Sung J. Proteolytic control of growth factor availability. APMIS 1999; 107: 80-85.
5. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22.
6. Carmeliet P, Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb Res 1998; 91: 255-285.
7. Blasi F. The urokinase receptor: A cell surface, regulated chemokine. APMIS 1999; 107: 96-101.
8. Stephens RW, Tapiovaara H, Reisberg T, Bizik J, Vaheri A. Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells. Cell Regul 1991; 2: 1057-1065.
9. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-195.
10. Ossowski L, Russo-Payne H, Wilson EL. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 1991; 51: 274-281.
11. Yu HR, Schultz RM. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 1990; 50: 7623-7633.
12. Frankenne F, Noël A, Bajou K et al. Molecular interactions involving urokinase uPA, its receptor uPAR and its inhibitor PAI-1 as new targets for tumour therapy. Emerging Therapeutic Targets 2000; in press.
13. Brünner N, Nielsen HJ, Hamers M, Christensen IJ, Thorlacius-Ussing O, Stephens RW. The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS 1999; 107: 160-167.
14. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Cur Opin Cell Biol 1997; 9: 714-724.
15. Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994; 269: 14746-14750.
16. Loskutoff DJ, Curriden SA, Hu G, Deng G. Regulation of cell adhesion by PAI-1. APMIS 1999; 107: 54-61.
17. Lindhal TL, Sigurdardottir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 1989; 62: 748-751.
18. Salonen EM, Vaheri A, Pöllänen J et al. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 1989; 264: 6339-6343.
19. Limongi P, Resnati M, Hernandez-Marrero L, Cremona O, Blasi F, Faziolo F. Biosynthesis and apical localization of the urokinase receptor in polarized MDCK epithelial cells. BEBS Lett 1995; 69: 207-211.
20. Estreicher A, Muhlhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990; 111: 783-792.
21. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587.
22. Stoop A, van Meijer M, Horrevoets AJG, Pannekoek H. Molecular advances in plasminogen activator inhibitor 1 interaction with thrombin and tissue-type plasminogen activator. Trends Cardiovasc Med 1997; 7: 47-51.
23. Knudson BS, Hapel PC, Nachman RL. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest 1987; 80: 1082-1089.
24. Stahl A, Mueller BM. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer 1997; 71: 116-122.
25. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-32388.
26. Deng G, Waltz DA, Navaneetha R, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-32388.
27. Kanse S, Kost C, Wilhelm O, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996; 224: 344-353.
28. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134: 1-9.
29. 3 binding to vitroncetin. Nature 1996; 383: 441-443.
30. Sugiura YML, Sun B, Shimada H, Laug WE, Seeger RC, DeClerck YA. The plasminogen-plasminogen activator (PA) system in neuroblastoma: Role of PA inhibitor-1 in metastasis. Cancer Res 1999; 59: 1327-1336.
31. KjØller L, Kanse SM, Kirkegaard T et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232: 420-429.
32. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, DanØ K. The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 1991; 51: 4067-4071.
33. Pepper M, Ferrara N, Orei L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991; 181: 902-906.
34. Stephens RW, Brünner N, Jänicke F, Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1998; 52: 99-111.
35. Pedersen H. Prognostic impact of urokinase, urokinase receptor, and type I plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-4675.
36. Donati MD. Cancer and thrombosis: From phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74: 278-281.
37. Eitzman DT, Krauss JC, Shen T, Cui J, Ginsburg D. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 1996; 87: 4718-4722.
38. Tsucjiya H, Katsuo E, Sunayama C, Tomita K, Ueda Y, Binder BR. The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice. Gen Diag Pathol 1995; 141: 41-48.
39. Bajou K, Noël A, Gerard R, et al. Absence of host plasminogen activator inhibitor-1 prevents cancer invasion and vascularization. Nature Med 1998; 4: 923-928.
40. Schnaper HW. Plasminogen activators augment endothelial organization in vitro by two distinct pathways. J Cell Physiol 1995; 165: 107-118.
41. Carmeliet P, Moons L, Lijnen R et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17: 436-444.
42. Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 1999; 340: 77-84.
43. Montesano R. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 1990; 62: 435-445.
44. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
45. Gately S, Twardowski P, Stack MS et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. PNAS 1997; 94: 10868-10872.